Dr David Baron/worldbrainmapping.org
Nov 14, 2024, 13:35
Adding CXB to Chemoradiotherapy in early Rectal Adenocarcinoma significantly improves outcomes
Iván R. González, Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla, shared an article by D. Baron on X:
“Interesting results from the Phase III OPERA trial show that adding contact X-ray brachytherapy(CXB) to chemoradiotherapy in early rectal adenocarcinoma significantly improves outcomes.
Key statistics:
- 5-year organ preservation rate: CXB 79% vs. 56% (p=0.004).
- For tumors <3 cm: CXB achieves a 93% preservation rate vs. 54%.
- Complete or near-complete clinical response by weeks 14-24: 92% with CXB vs. 64% (p<0.001).
- 3-year organ preservation: CXB 81% vs. 59% (p=0.003).
Controlled side effects: rectal bleeding (grade 1-2) decreased after 3 years, with no impact on bowel function.
CXB offers new hope for organ preservation, especially in small tumors, with close monitoring advised.”
Authors: D. Baron, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 13:37
Nov 14, 2024, 13:32
Nov 14, 2024, 13:29
Nov 14, 2024, 13:02
Nov 14, 2024, 12:44